Might want to atleast wait until a larger phase 2 blinded study before proclaiming the drug works.
Don't really know if you've been following the P1 study.
They're going directly into a Pivotal Phase 2 study with '534. Considering they will likely get a Ophan status for this drug in the T315i portion of CML patients, I believe it will be granted an expedited approval (much like Gleevec was).
They're not going for "front line" which would take a longer trial as you suggest.
Market Data 
Markets 
AI
